By: Heather Biele, Mark Leiser
The time between biopsy and ordering of tissue-based comprehensive genomic profiling varies widely between clinical sites, according to study results.
Mark Leiser is a content strategist at Healio, specializing in hematology/oncology and cellular therapy. With a background in medical publishing since 2011, he focuses on various themes including oncology, immunotherapy, and wellness programs, aiming to provide valuable insights into medicine and healthcare. Leiser's work has been recognized in multiple prestigious awards, and he is featured in Healio.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)


Not enough data
Mark's coverage indicates a strong focus on healthcare and pharmaceuticals, particularly in the context of clinical trial data and scientific breakthroughs. He is most likely to be interested in pitches that provide access to exclusive data or insights related to new treatments for cancer, hemophilia, gene therapy, or other significant medical advancements.
Given Mark’s reliance on citing data, he may respond well to expert sources who can offer detailed analysis of clinical trial results or scientific developments in the mentioned fields. Pitches should emphasize the depth of expertise and ability to provide unique perspectives based on robust evidence.
It is important for potential contributors reaching out to Mark Leiser with relevant information regarding recent discoveries or groundbreaking research within these specialized areas.
This information evolves through artificial intelligence and human feedback. Improve this profile .